Further, we describe the mode of action of ICI aimed at counteracting the anti-inflammatory effects of IC, which in the case of anti-CTLA-4 and anti-PD-1 have been granted early approval for melanoma treatment. The gene discussed is CTLA4; the disease is melanoma.